Indigo Naturalis for Eczema: Vehicle-Controlled Results Versus a Small Tacrolimus Comparison
A trial showing that an ointment performs better than its vehicle does not tell us whether it performs as well as an established medicine. Indigo naturalis oil extract, studied as Lindioil ointment, illustrates why the comparison matters. The evidence is worth examining without turning it into an endorsement of every product described as herbal or indigo-based.
The 2020 trial compared a specific ointment with vehicle
The 2020 randomized, double-blind trial enrolled 48 participants aged 6–65 and allocated them 2:1 to Lindioil or vehicle twice daily for six weeks. The publisher's primary report describes mean Eczema Area and Severity Index reductions of 49.9% in 32 participants versus 19.6% in 16 controls; P=0.0235. These are mean percentage changes, not the percentages of people who cleared their eczema.
Thirty-five participants completed the full study. Short duration and incomplete completion limit conclusions about sustained control and less common harms. A result for this formulated oil-extract ointment cannot be assigned to a powder, homemade mixture or product with a different composition.
The 2025 comparison was much smaller than planned
The 2025 randomized crossover study compared Lindioil with tacrolimus 0.1% in six-week treatment periods. Although eligibility allowed younger patients, all 22 randomized participants were adults aged 20.8–44.3. The target sample was 123; recruitment was curtailed during the pandemic. All 22 completed the first period, but only 14 completed the second.
| Study | Finding and boundary |
|---|---|
| Lindioil, six-week EASI | 6.6 to 3.4 |
| Tacrolimus, six-week EASI | 6.7 to 1.9 |
| Interpretation | Both improved from baseline; that is not proof of equivalence |
Between-treatment changes in itch and quality-of-life scores favored tacrolimus. Across the trial, 19 participants experienced 56 adverse events; none was severe. This small, evaluator-blinded crossover study cannot establish comparable long-term efficacy or broadly superior safety. In particular, a nonsignificant difference in one outcome would not by itself prove noninferiority.
Ask which question a result actually answers
The first study asks whether adding the studied extract to its vehicle changes eczema outcomes. The second compares two active products under a different design. Reading their results as interchangeable erases important differences in population, masking, exposure and completion.
A helpful appointment question is: “Does this evidence apply to the exact product, strength, age group and duration being considered?” Follow it with questions about the expected benefit, monitoring and what would happen if the product irritates the skin or does not help. Our guide to interpreting eczema research explains the difference between improvement within a group and a reliable comparison between groups.
Keep the formulation and route explicit
A topical ointment trial cannot establish the safety of swallowing an herb or using a home-prepared extract. The broader herbal-medicine evidence review addresses why ingredients, processing and study quality matter. Do not stop or replace a prescribed treatment simply because an alternative is described as natural.
The AAD guideline summary supports topical calcineurin inhibitors among established treatment options. Questions about tacrolimus and pimecrolimus belong in the treatment discussion, including tolerability and correct use. A patient's concerns deserve an explanation grounded in the relevant evidence rather than assuming that a newer small trial settles every benefit–risk question.
For another formulation-specific example, see the honey pilot and randomized trial comparison. The details of the product and control matter in each case; results cannot be transferred between them.
A separate role for cosmetic moisturizing
Dr. Arsy Moisturizer #003, 4 oz / 120 g is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema, replace prescribed care, or inherit results from the study products discussed here. Adult cosmetic testing does not establish infant or pediatric suitability. Read the actual ingredient label and consider individual tolerability.
Educational information, not an individual treatment plan. Sources checked November 9, 2026. The sports image is an AI-created editorial product visual, not a patient photo or a clinical outcome.